A new study shows that the way amyloid proteins—implicated in Alzheimer's disease—assemble into fibrils can be significantly ...

Adopting intensive lifestyle changes can slow or stop progression of early-stage Alzheimer’s disease, according to a new ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

The first clinical guidelines on the use of blood biomarker tests could help clinicians choose the most appropriate test to ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

A hit Bollywood film sparks public curiosity about early-onset Alzheimer’s — experts break down its causes, symptoms, and how ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Data from Most Deeply Characterized Cohort Across Alzheimer's Disease Released by Global Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative ...

ALZpath’s pTau217 antibody was released in 2023 and continues to be a key focus in Alzheimer’s disease research and ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...